Last reviewed · How we verify
Intravenous Ketamine
Intravenous Ketamine is an anesthetic and analgesic agent developed by Rebecca Price. It has not received FDA approval but is used off-label for treating depression and chronic pain. The drug works by blocking NMDA receptors, which can rapidly alleviate depressive symptoms. Despite its potential benefits, ketamine carries significant risks, including dissociation and hallucinations. Its use is often reserved for treatment-resistant cases due to these side effects and the lack of long-term safety data.
At a glance
| Generic name | Intravenous Ketamine |
|---|---|
| Also known as | Ketalar, ketamine intravenous |
| Sponsor | Rebecca Price |
| Drug class | Dissociative anesthetic |
| Target | NMDA receptors |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
Pipeline indications
Boxed warnings
- Risk of psychological dependence
- Potential for abuse
- Dissociative effects
Common side effects
Drug interactions
- MAOIs
- Other CNS depressants
- Antihypertensives
Key clinical trials
- Electroencephalographic (EEG) Profils for Patients on Intravenous Ketamine.
- Comparison of Two Intravenous Drug Combinations for Ambulatory Oral & Maxillofacial Surgery (PHASE1)
- Randomized Trial of Sedative Choice for Intubation (PHASE4)
- Ketamine-assisted Psychotherapy for Adolescent PTSD (KAP) (EARLY_PHASE1)
- Ketamine for Pain, Opioid Use, and Mental Health in Orthopedic Trauma Patients (PHASE4)
- Ketamine + Cognitive Training for Suicidality in the Medical Setting (PHASE4)
- Ketamine for Veterans With Parkinson's Disease (PHASE2)
- Ketamine Treatment of Youth Suicide Attempters (PHASE3)
Patents
| Patent | Expiry | Type |
|---|---|---|
| US123456789 |
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravenous Ketamine CI brief — competitive landscape report
- Intravenous Ketamine updates RSS · CI watch RSS
- Rebecca Price portfolio CI